UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 7, 2009

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other Jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

[X ] Written communication pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events

On April 7, 2009, Pfizer Inc. issued a press release announcing the operating

structure of the Company and certain senior leadership positions that

will be effective upon the closing of its acquisition of Wyeth. A copy

of the press release is attached hereto as Exhibit 99.1 and is incorporated

by reference herein. On April 7, 2009, Pfizer also distributed a letter

from Pfizer Chairman and CEO, Jeffrey B. Kindler, to Pfizer's employees.

A copy of the letter to employees is attached hereto as Exhibit 99.2 and

is incorporated by reference herein..

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

99.1

Pfizer Inc. Press Release dated April 7, 2009

99.2

Letter to Pfizer Employees

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Matthew Lepore

Matthew Lepore

Title: Vice President, Chief Counsel - Corporate Governance,

and Assistant General Counsel

Dated: April 7, 2009

EXHIBIT INDEX

Exhibit No.

Description

99.1

Pfizer Inc. Press Release dated April 7, 2009

99.2

Letter to Pfizer Employees